arrow_back Back Filing freshness 10-Q FY 2025 SEC EDGAR

VERU INC.

VERU
$2.31 ▲ +0.02 (+0.65%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
18 Visible periods
34 Metrics
Peer-ranked Benchmarks
Price Chart
22
Health
Poor
Bearish
auto_awesome

Analytical Summary

VERU INC. faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $33.8M
Dividend Yield
Revenue Growth None
Op. Margin None
ROIC -106.7%
FCF / Share $-2.05
Trailing P/E
Price / Book 1.9x
FCF Yield
Debt / Equity
info Valuation on last close. End-of-day price, Aug 7, 2026.

18-Year Financial Trajectory

Annual
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$16.89M
↑ +3.6%
Net Income Profit after all expenses
$-22.73M
↑ +39.9%
Operating Margin Operating profit as % of sales
-218.6%
↓ -3.4%
FCF / Share Free cash flow per share
$-2.05
↓ -1166.8%
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns
6
Financial Health
15
Cash Quality
76

Dividend History

Dividend / share · sourced from SEC filings
$0.21 Latest / share

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 18 years · 67 quarters